These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 30311576)

  • 1. Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma.
    Hong M; Tang K; Qian J; Deng H; Zeng M; Zheng S; Ding K; Du Y; Sun R
    Crit Rev Oncog; 2018; 23(3-4):219-234. PubMed ID: 30311576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic approaches in nasopharyngeal carcinoma.
    Chow JC; Ngan RK; Cheung KM; Cho WC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1165-1172. PubMed ID: 31361154
    [No Abstract]   [Full Text] [Related]  

  • 3. Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer.
    Lee AZE; Tan LSY; Lim CM
    Oral Oncol; 2018 Sep; 84():61-70. PubMed ID: 30115477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma.
    Li W; Duan X; Chen X; Zhan M; Peng H; Meng Y; Li X; Li XY; Pang G; Dou X
    Front Immunol; 2022; 13():1079515. PubMed ID: 36713430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
    Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for nasopharyngeal cancer-a review.
    Jain A; Chia WK; Toh HC
    Chin Clin Oncol; 2016 Apr; 5(2):22. PubMed ID: 27121882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of NK Cells in EBV Infection and EBV-Associated NPC.
    Png YT; Yang AZY; Lee MY; Chua MJM; Lim CM
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33671917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review).
    Huang H; Yao Y; Deng X; Huang Z; Chen Y; Wang Z; Hong H; Huang H; Lin T
    Int J Oncol; 2023 Aug; 63(2):. PubMed ID: 37417358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era.
    Wang S; Chen S; Zhong Q; Liu Y
    J Cancer Res Clin Oncol; 2023 May; 149(5):2071-2079. PubMed ID: 35876949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatiotemporal homogeneity and distinctness of the T-cell receptor β-chain repertoires in Epstein-Barr virus-associated primary and metastatic nasopharyngeal carcinomas.
    Chung YL; Wu ML
    Int J Cancer; 2018 Aug; 143(3):610-620. PubMed ID: 29468660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year disease-free survival of Epstein-Barr virus-associated locoregionally advanced undifferentiated nasopharyngeal carcinoma patients treated with chemo-radiotherapy: a case report.
    Wang N; Wang H; Jiang H; Bi Y; Zhao Y; He X; Cao F; Yuan Y
    Ann Palliat Med; 2022 Mar; 11(3):1147-1152. PubMed ID: 35365045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?
    Juarez-Vignon Whaley JJ; Afkhami M; Onyshchenko M; Massarelli E; Sampath S; Amini A; Bell D; Villaflor VM
    Curr Treat Options Oncol; 2023 Sep; 24(9):1138-1166. PubMed ID: 37318724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Stage and Locally Advanced Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Going?
    Juarez-Vignon Whaley JJ; Afkhami M; Sampath S; Amini A; Bell D; Villaflor VM
    Curr Treat Options Oncol; 2023 Jul; 24(7):845-866. PubMed ID: 37145382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
    Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EBV Infection and Glucose Metabolism in Nasopharyngeal Carcinoma.
    Zhang J; Jia L; Tsang CM; Tsao SW
    Adv Exp Med Biol; 2017; 1018():75-90. PubMed ID: 29052133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus as a paradigm in nasopharyngeal cancer: from lab to clinic.
    Raghupathy R; Hui EP; Chan AT
    Am Soc Clin Oncol Educ Book; 2014; ():149-53. PubMed ID: 24857071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating Epstein-Barr Virus: An analysis of a prospective study in southern China.
    Hu T; Lin CY; Xie SH; Chen GH; Lu YQ; Ling W; Huang QH; Liu Q; Cao SM
    Cancer Med; 2019 May; 8(5):2561-2571. PubMed ID: 30843658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus infection and nasopharyngeal carcinoma.
    Tsao SW; Tsang CM; Lo KW
    Philos Trans R Soc Lond B Biol Sci; 2017 Oct; 372(1732):. PubMed ID: 28893937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus infection and nasopharyngeal carcinoma: the other side of the coin.
    Perri F; Della Vittoria Scarpati G; Giuliano M; D'Aniello C; Gnoni A; Cavaliere C; Licchetta A; Pisconti S
    Anticancer Drugs; 2015 Nov; 26(10):1017-25. PubMed ID: 26241803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.